Some HIV clinics changing protocols on anergy. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Some HIV clinics changing protocols on anergy. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Alert. 1995 Apr;10(4):suppl 1-2. Unique Identifier : AIDSLINE AIDS/95700230

Abstract: The Centers for Disease Control and Prevention (CDC) has advised health care workers to evaluate HIV-positive people for delayed-type hypersensitivity (DTH) anergy at the time of PPD (purified protein derivative) testing. However, controversy remains among those that feel anergy testing is either unnecessary or inaccurate. A study conducted by researchers at the Johns Hopkins University in Baltimore, MD, demonstrated that anergy test results were not stable. If CD4 counts are above 500, it is highly unlikely that they will be anergic. Anergy testing may be just as unnecessary in patients with low CD4 counts. People with CD4 counts less than 200 are very likely to be anergic. The CDC recommends that if patients are anergic, those with a high risk of TB infection should be given prophylaxis. Researchers at Hopkins suggest that clinicians look closely at rates of prevalence and incidence within the patient's community. Given limited resources, and limited incidence and prevalence of TB, Hopkins representatives suggest providers concentrate efforts on PPD-positive patients.
Keywords: Human Hypersensitivity, Delayed/IMMUNOLOGY HIV Infections/*COMPLICATIONS Tuberculin Test/*UTILIZATION Tuberculosis/*DIAGNOSIS NEWSLETTER ARTICLEKWDhumanhypersensitivity,delayed/immunologyhivinfections/KWDcomplicationstuberculintest/KWDutilizationtuberculosis/KWDdiagnosisnewsletterarticle
951030
M95A0954

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .